

In the claims:

1-32. (cancelled)

33. **(amended)** An antibody or fragment thereof which binds to a mature B7RP1 polypeptide as set forth in Figure 2A (SEQ ID NO:7) comprising a mature amino terminus at residue 47 ~~or a mature form thereof~~.

34. **(amended)** An antibody or fragment thereof which binds to a mature B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24 or 28 ~~or a mature form thereof~~.

35. **(amended)** An antibody or fragment thereof which binds to a mature B7RP1 polypeptide as set forth in Figure 12A (SEQ ID NO:17) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24 or 28 ~~or a mature form thereof~~.

36. **(amended)** An antibody or fragment thereof which specifically binds to a mature ~~form of a~~ B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24 or 28.

37. **(amended)** An antibody or fragment thereof which binds to a mature ~~form of a~~ B7RP1 polypeptide as set forth in Figure 12A (SEQ ID NO:17) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24 or 28, and to a mature form of a B7RP1 polypeptide as set forth in Figure 2A SEQ ID NO:7) comprising a mature amino terminus at residue 47.

38. **(amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a membrane-associated form of a the B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

39. **(amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a soluble form of a the B7RP-1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

40. **(amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to an extracellular domain, ~~or fragment thereof~~, of a the B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17), or a fragment thereof comprising at least about 25, 50, 75, 100 or greater than 100 amino acid residues.

41. The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely blocks the binding of B7RP1 to CRP1.

42. The antibody or fragment of Claims 34, 35, 36 or 37 which is an antibody that increases B7RP-1 mediated T cell costimulatory activity.

43. The antibody or fragment of Claims 34, 35, 36 or 37 which is an antibody that decreases B7RP-1 mediated T cell costimulatory activity.

44. The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely inhibits B7RP-1 mediated T cell costimulatory activity.

45. **(amended)** An antibody or fragment thereof which binds to a mature B7RP-1 polypeptide encoded by the nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6).

46. **(amended)** An antibody or fragment thereof which binds to a mature B7RP-1 polypeptide encoded by the nucleotide sequence as set forth in Figure 3A (SEQ ID NO: 11) or Figure 12A (SEQ ID NO: 16).

47. **(amended)** An antibody or fragment thereof which binds to the extracellular domain ~~a soluble form~~ of B7RP1, wherein B7RP1 is encoded by the nucleic acid as set forth in Figure 3A (SEQ ID NO:11) or Figure 12A (SEQ ID NO:16).

48. The antibody of Claims 34, 35, 36 or 37 which is a monoclonal antibody.

49. The antibody of Claims 34, 35, 36 or 37 which is a chimeric antibody.

50. The antibody of Claims 34, 35, 36 or 37 which is a single chain antibody.

51. The antibody of Claims 34, 35, 36 or 37 which is a bispecific antibody.
52. The antibody of Claims 34, 35, 36 or 37 which is a CDR-grafted or humanized antibody.
53. The antibody of Claims 34, 35, 36 or 37 which is a human antibody.
54. A pharmaceutical composition comprising the antibody of Claims 34, 35, 36 or 37 and a carrier, diluent, and/or excipient.